Condition
Salivary Duct Carcinoma
Total Trials
6
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
6Total
Not Applicable (2)
P 1 (1)
P 2 (3)
Trial Status
Completed2
Unknown2
Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT05513365Phase 2RecruitingPrimary
Phase II Dutasteride in Combination With CAB vs CAB in SDC
NCT04249947Phase 1Terminated
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
NCT04291300Phase 2Completed
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
NCT04214353Not ApplicableUnknown
PSMA-PET Imaging Before and After ADT in Advanced SDC Patients
NCT03614364Phase 2UnknownPrimary
Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma
NCT03319641Not ApplicableCompleted
PSMA-PET Imaging for Advanced ACC/SDC
Showing all 6 trials